Skip to main content
SpringerLink
Log in

Integration of Chemotherapy in the Management of Locally Advanced Non-Small-Cell Lung Cancer

  • Chapter
Book cover Tumors of the Chest

  • 815 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 179.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Hennequin C, Favaudon V. Biological basis for chemoradiotherapy interactions. Eur J Cancer 2002; 38:223.

    Article  PubMed  CAS  Google Scholar 

  2. Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 1994; 86:673.

    PubMed  CAS  Google Scholar 

  3. Rosell R, Gomez-Codina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994; 330:153.

    Article  PubMed  CAS  Google Scholar 

  4. Depierre A, Milleron B, Moro-Sibilot D, et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 2002; 20:247.

    Article  PubMed  Google Scholar 

  5. Cappuzzo F, De Marinis F, Nelli F, et al. Phase II study of gemcitabine-cisplatin-paclitaxel triplet as induction chemotherapy in inoperable, locally advanced non-small cell lung cancer. Lung Cancer 2003; 42:355.

    Article  PubMed  Google Scholar 

  6. Cappuzzo F, Selvaggi G, Gregorc V, et al. Gemcitabine and cisplatin as induction chemotherapy for patients with unresectable stage IIIA-bulky N2 and stage IIIB non small cell lung carcinoma. Cancer 2003; 98:128.

    Article  PubMed  CAS  Google Scholar 

  7. O’Brien MER, Splinter T, Smit EF, et al. Carboplatin and paclitaxel (Taxol) as an induction regimen for patients with biopsy-proven stage IIIA N2 non-small cell lung cancer: an EORTC phase II study (EORTC 08958). Eur J Cancer 2003; 39:1416.

    Article  PubMed  CAS  Google Scholar 

  8. Albain KS, Rusch VW, Crowley JJ, et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIAN2 and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 2001; 13:1880.

    Google Scholar 

  9. Albain KS, Crowley JJ, Turrisi AT 3rd, et al. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol 2002;20:3454.

    Article  PubMed  CAS  Google Scholar 

  10. Albain KS, Scott CB, Rusch VR, et al. Phase III comparison of concurrent chemotherapy plus radiotherapy (CT/RT) and CT/RT followed by surgical resection for stage IIIA (pN2) non-small cell lung cancer: initial results from intergroup trial 0139 (RTOG 93-09). Proc Am Soc Clin Oncol 2003; 22:621.

    Google Scholar 

  11. Betticher DC, Hsu Schmitz S-F, Totsch M, et al. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. J Clin Oncol 2003; 21:1752.

    Article  PubMed  CAS  Google Scholar 

  12. Rosell R. The integration of newer agents into neoadjuvant therapy. Semin Oncol 1998; 25(suppl 8):24.

    PubMed  CAS  Google Scholar 

  13. Gandara DR, Lara PN Jr, Goldberg Z, Roberts P, Lau DH. Neoadjuvant therapy for non-small cell lung cancer. Anticancer Drugs 2001; 12(suppl 1):S5.

    PubMed  CAS  Google Scholar 

  14. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 1995; 311:899.

    Google Scholar 

  15. Dillman RO, Herndon J, Seagren SL, Eaton WL, Green MR. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial. J Natl Cancer Inst 1996;88:1210.

    PubMed  CAS  Google Scholar 

  16. Sause W, Kolesar P, Taylor S IV, et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer. Radiation Therapy Oncology, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 2000; 117:358.

    Article  PubMed  CAS  Google Scholar 

  17. Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med 1992; 326:524.

    Article  PubMed  CAS  Google Scholar 

  18. Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study. J Clin Oncol 1996; 14:1065.

    PubMed  CAS  Google Scholar 

  19. Curran WJ Jr, Scott CB, Langer CJ, et al. Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III NSCLC: rTOG 9410. Proc Am Soc Clin Oncol 2003; 22:621.

    Google Scholar 

  20. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer. J Clin Oncol 1999; 17:2692.

    PubMed  CAS  Google Scholar 

  21. Movsas B, Scott C, Curran W, Byhardt R, Langer C. A quality-adjusted time without symptoms or toxicity (QTWiST) analysis of Radiation Therapy Oncology Group (RTOG) 94-10. Proc Am Soc Clin Oncol 2001; 20:313a.

    Google Scholar 

  22. Movsas V, Moughan J, Komaki R, et al. Radiotherapy (RT) patterns of care study (PCS) in lung carcinoma. J Clin Oncol 2003; 21:4553.

    Article  PubMed  CAS  Google Scholar 

  23. Lau D, Leigh B, Gandara DR, et al. Twice weekly paclitaxel and weekly carboplatin with concurrent thoracic irradiation followed by carboplatin/paclitaxel consolidation for stage III non-small cell lung cancer: a California Cancer Consortium phase II trial. J Clin Oncol 2001; 19:442.

    PubMed  CAS  Google Scholar 

  24. Vokes EE, Herndon II JE, Crawford J, Leopold KA, Perry MC, Miller AA, Green MR. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: Cancer and Leukemia Group B study 9431. J Clin Oncol 2002; 20:4191.

    Article  PubMed  CAS  Google Scholar 

  25. Gridelli C, Guida C, Barletta E, et al. Thoracic radiotherapy and daily vinorelbine as radiosensitizer in locally advanced non small cell lung cancer: a phase I study. Lung Cancer 2000; 29:131.

    Article  PubMed  CAS  Google Scholar 

  26. Gandara DR, Chansky K, Albain KS, et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group (S9504). J Clin Oncol 2003; 21:2004.

    Article  PubMed  CAS  Google Scholar 

  27. Choy H, Curran WJ, Scott CB, et al. Preliminary report of locally advanced multimodality protocol (LAMP): aCR 427: a randomized phase II study of three chemo-radiation regimens with paclitaxel, carboplatin, and thoracic radiation (TRT) for patients with locally advanced non small cell lung cancer (LA-NSCLC). Proc Am Soc Clin Oncol 2002; 21:291a.

    Google Scholar 

  28. Raymond R, Faivre S, Armand J. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs 2000; 60(suppl 1):15.

    Article  PubMed  CAS  Google Scholar 

  29. Dent P, Reardon D, Park J, Bowers G, Logsdon C, Valerie K, Schmidt-Ullrich R. Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol Biol Cell 1999; 10:2493.

    PubMed  CAS  Google Scholar 

  30. Akimoto T, Hunter NR, Buchmiller L, Masou K, Ang KK, Milas L. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res 1999; 5:437.

    Google Scholar 

  31. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999; 59:1935.

    PubMed  CAS  Google Scholar 

  32. Bianco C, Tortora G, Bianco R, et al. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res 2002; 8:3250.

    PubMed  CAS  Google Scholar 

  33. Baselga J, Herbst R, LoRusso P, et al. Continuous administration of ZD1839 (Iressa), a novel oral epidermal growth factor tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tumor types: evidence of activity and good tolerability. Proc Am Soc Clin Oncol 2000; 19:177a.

    Google Scholar 

  34. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290:2149.

    Article  PubMed  CAS  Google Scholar 

  35. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21:2237.

    Article  PubMed  CAS  Google Scholar 

  36. Shepherd FA, Pereira J, Ciuleanu TE, et al. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2004; 22(14S):7022.

    Google Scholar 

  37. Rischin D, Burmeister B, Mitchell P, et al. Phase I trial of gefitinib (ZD1839) in combination with concurrent carboplatin, paclitaxel and radiation therapy in patients with stage III non-small cell lung cancer. ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2004; 22(14S):7077.

    Google Scholar 

  38. Steinauer KK, Gibbs I, Ning S, French JN, Armstrong J, Knox SJ. Radiation induces upregulation of cyclooxygenase-2 (COX-2) protein in PC-3 cells. Int J Rad Oncol Biol Phys 2000; 48:325.

    Article  CAS  Google Scholar 

  39. Teicher BA, Depuis NP, Kusumoto T, et al. Anti-angiogenic agents can increase tumor oxygenation and response to radiation therapy. Radiat Oncol Invest 1995;2:269.

    Google Scholar 

  40. Kishi K, Petersen C, Hunter N, et al. Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res 2000; 60:1326.

    PubMed  CAS  Google Scholar 

  41. Altorki NK, Keresztes RS, Port JL, et al. Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J Clin Oncol 2003;21:2631.

    Article  CAS  Google Scholar 

  42. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184.

    Article  PubMed  CAS  Google Scholar 

  43. Keiko S, Komaki R, Wenjuan W, et al. Targeted therapy against VEGF and EGF signaling with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic mouse model of human non-small cell lung cancer. Proceedings of the 46th Annual Meeting of American Society of Therapeutic Radiology and Oncology, October 3–7, 2004, abstract 35.

    Google Scholar 

  44. Gridelli C, Perrone F, Monfardini S. Lung cancer in the elderly. Eur J Cancer 1997; 33:2313.

    Article  PubMed  CAS  Google Scholar 

  45. Havlik RJ, Yancik R, Long S, Ries L, Edwards B. The National Cancer Institute on Aging and the National Cancer Institute SEER. Collaborative study on comorbidity and early diagnosis of cancer in the elderly. Cancer 1994; 74(suppl 7):2101.

    Article  PubMed  CAS  Google Scholar 

  46. Janssen-Heijnen MLG, Schipper RM, Razenberg PPA, Crommelin MA, Coebergh JW. Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: a population-based study. Lung Cancer 1998; 21:105.

    Article  PubMed  CAS  Google Scholar 

  47. Zimmermann FB, Molls M, Jeremic B. Treatment of locally advanced and metastatic non-small cell lung cancer in the elderly. Hematol Oncol Clin North Am 2004;18:203.

    Article  PubMed  Google Scholar 

  48. Atagi S, Kawahara M, Ogawara M, et al. Phase II trial of daily low-dose carboplatin and thoracic radiotherapy in elderly patients with locally advanced non-small cell lung cancer. Jpn J Clin Oncol 2000; 30:59.

    Article  PubMed  CAS  Google Scholar 

  49. Nakano K, Yamamoto M, Iwamoto H, Hiramoto T. Daily low-dose cisplatin plus concurrent high-dose thoracic radiotherapy in elderly patients with locally advanced unresectable non-small-cell lung cancer. Gan To Kagaku Ryoho 2003; 30:1283.

    PubMed  Google Scholar 

  50. D’Angelillo RM, Trodella L, Ramella S, et al. Neoadjuvant chemoradiotherapy followed by surgery in elderly patients with locally advanced non-small cell lung cancer: analysis of feasibility, toxicity and factors predicting surgical resection and survival. Proc Am Soc Clin Oncol 2004;23:654.

    Google Scholar 

  51. Movsas B, Scott C, Sause W, et al. The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): a quality-adjusted survival analysis of radiation therapy oncology group (RTOG) chemoradiation studies. Int J Radiat Oncol Biol Phys 1999; 45:1143.

    Article  PubMed  CAS  Google Scholar 

  52. Werner-Wasik M, Scott C, Cox JD, et al. Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival. Int J Radiat Oncol Biol Phys 2000;48:1475.

    Article  PubMed  CAS  Google Scholar 

  53. Langer C, Scott C, Byhardt R, et al. Effect of advanced age on outcome in Radiation Therapy Oncology Group studies of locally advanced NSCLC. Lung Cancer 2000; 29(suppl 1):119.

    Google Scholar 

  54. Langer CJ, Hsu C, Curran WJ, et al. Elderly patients with locally advanced non-small cell lung cancer benefit from combined modality therapy: secondary analysis of Radiation Therapy Oncology Group (RTOG) 94-10. Proc Am Soc Clin Oncol 2002; 21:299a.

    Google Scholar 

  55. Schild SE, Stella PJ, Geyer SM, et al; North Central Cancer Treatment Group. The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. J Clin Oncol 2003; 21:3201.

    Article  PubMed  CAS  Google Scholar 

  56. Perrone F, Gallo C, Gridelli C. Re: Cisplatin-based therapy for elderly patients with advanced non-small cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 2002;94:1029.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Medical Oncology, S.G. Moscati Hospital, Avellino, Italy

    Cesare Gridelli & Paolo Maione

Authors
  1. Cesare Gridelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paolo Maione
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Sotiria General Hospital, Athens Medical School, Athens, Greece

    Konstantinos N. Syrigos MD, PhD

  2. Royal Marsden NHS Trust Hospitals, London, UK

    Christopher M. Nutting MB BA, MD, FRCR

  3. Evangelismos General Hospital, Athens Medical School, Athens, Greece

    Charis Roussos MD, MSc, PhD, MRS, FRCP(C)

  4. Faculty of Medicine, McGill University, Montreal, Canada

    Charis Roussos MD, MSc, PhD, MRS, FRCP(C)

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer Berlin Heidelberg

About this chapter

Cite this chapter

Gridelli, C., Maione, P. (2006). Integration of Chemotherapy in the Management of Locally Advanced Non-Small-Cell Lung Cancer. In: Syrigos, K.N., Nutting, C.M., Roussos, C. (eds) Tumors of the Chest. Springer, Berlin, Heidelberg . https://doi.org/10.1007/3-540-31040-1_20

Download citation

  • DOI: https://doi.org/10.1007/3-540-31040-1_20

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-31039-6

  • Online ISBN: 978-3-540-31040-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation